BD a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
The BD Neopak™ Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs and our customers have received approval to utilize this platform for more than 24 indications, including Crohn's disease, atopic dermatitis, cardiovascular disease and various rare diseases.
BD has expanded usability of this platform with the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity1,2*. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today's limits versus a standard half-inch needle3*.
"BD is seeing significant growth in the biologics segment, driven by novel drug formulations across indications such as metabolic disorders and oncology," said Patrick Jeukenne, president of BD Pharmaceutical Systems. "With over 30 drugs approved across 12 markets and many more in development with the BD Neopak™ Glass Prefillable Syringe platform, flexibility is crucial. As a global leader in prefillable drug-delivery systems, BD aims to evolve as rapidly as the global biologics pipeline to enable supply and delivery of these drugs for patients worldwide."
In addition to the usability enhancements, our manufacturing site in Le Pont-de-Claix, France has successfully integrated a high-volume manufacturing line for the BD Neopak™ Glass Prefillable Syringe platform, increasing the production capacity of a single line by sevenfold4. This achievement marks a significant milestone for BD, enabling unprecedented large-scale production of advanced BD glass syringes.
The launch of our BD Neopak™ XtraFlow™ Glass Prefillable Syringe allows developers to take advantage of a single platform approach while dismantling existing design barriers such as drug viscosity. The successful addition of the high-volume line at the Pont-de-Claix site allows BD to be more resilient to supply constraints and further demonstrates our commitment to continuously evolve to meet the needs of our pharmaceutical partners and patients worldwide. These expansions add to BD's leadership in offering a broad range of injection solutions to enable delivery of treatments such as GLP-1s, antibodies, and other next generation treatments for chronic disease.
For more information please visit www.bd.com
